Download PDF
Hamostaseologie 2020; 40(03): 348-355
DOI: 10.1055/a-1171-3995
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Use of Anticoagulants in Patients with Pulmonary Hypertension

Laurent Bertoletti
1   Service de MédecineVasculaire et Thérapeutique, CHU de St-Etienne, Saint-Etienne, France
2   INSERM, UMR1059, EquipeDysfonctionVasculaire et Hémostase, Université Jean-Monnet, Saint-Etienne, France
3   INSERM, CIC-1408, CHU Saint-Etienne, Saint-Etienne, France
4   F-CRIN INNOVTE Network, Saint-Etienne, France
,
Valentine Mismetti
1   Service de MédecineVasculaire et Thérapeutique, CHU de St-Etienne, Saint-Etienne, France
5   Service de Pneumologie, CHU de St-Etienne, St-Etienne, France
,
George Giannakoulas
6   Department of Cardiology, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece
› Author Affiliations
Further Information

Publication History

24 January 2020

05 May 2020

Publication Date:
29 July 2020 (online)

Also available at
   Permissions and Reprints

Abstract

Since the earliest works on the understanding of different forms of pulmonary hypertension, thrombosis has been involved in the pathophysiology of the disease, both in pulmonary arterial hypertension (PAH) and in chronic thromboembolic pulmonary hypertension (CTEPH). Autopsy and then pathophysiological data paved the way for the use of anticoagulants as a treatment for PAH and CTEPH. In PAH their role has diminished with the advent of specific targeted therapies, but they are still prescribed in more than half of PAH patients, because of concomitant venous thromboembolism or atrial fibrillation. In CTEPH long-term anticoagulant therapy is the cornerstone of the management. The recent development of direct oral anticoagulants (DOACs) raises the question of the best anticoagulation strategy, both in patients with PAH and in patients with CTEPH. In this review, we present an overview of the history of anticoagulants in the management of patients suffering from PAH or CTEPH, an update of the available data on the underlying rationale of their use in these subjects, an alert on the potential risks of using DOACs in these poorly explored situations, and the setting up of dedicated trials to evaluate the best anticoagulant treatment strategies in patients suffering from PAH or CTEPH.

Keywords

anticoagulant - pulmonary hypertension - venous thromboembolism - bleeding
 

  • References

  • 1 Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J 2019; 53 (01) 1802148
    CrossrefPubMedGoogle Scholar
  • 2 Simonneau G, Montani D, Celermajer DS. , et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53 (01) 1801913
    CrossrefPubMedGoogle Scholar
  • 3 Abenhaim L, Moride Y, Brenot F. , et al; International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335 (09) 609-616
    CrossrefPubMedGoogle Scholar
  • 4 Guignabert C, Tu L, Girerd B. , et al. New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication. Chest 2015; 147 (02) 529-537
    CrossrefPubMedGoogle Scholar
  • 5 Galiè N, Humbert M, Vachiery J-L. , et al; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37 (01) 67-119
    CrossrefPubMedGoogle Scholar
  • 6 Bertoletti L, Ollier E, Duvillard C. , et al. Direct oral anticoagulants: current indications and unmet needs in the treatment of venous thromboembolism. Pharmacol Res 2017; 118: 33-42
    CrossrefPubMedGoogle Scholar
  • 7 Humbert M, Guignabert C, Bonnet S. , et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J 2019; 53 (01) 1801908
    CrossrefPubMedGoogle Scholar
  • 8 Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70 (04) 580-587
    CrossrefPubMedGoogle Scholar
  • 9 Christ G, Graf S, Huber-Beckmann R. , et al. Impairment of the plasmin activation system in primary pulmonary hypertension: evidence for gender differences. ThrombHaemost 2001; 86 (02) 557-562
    PubMedGoogle Scholar
  • 10 Huber K, Beckmann R, Frank H, Kneussl M, Mlczoch J, Binder BR. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med 1994; 150 (04) 929-933
    CrossrefPubMedGoogle Scholar
  • 11 Herve P, Humbert M, Sitbon O. , et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 2001; 22 (03) 451-458
    CrossrefPubMedGoogle Scholar
  • 12 Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J 1998; 12 (06) 1446-1449
    CrossrefPubMedGoogle Scholar
  • 13 Miniati M, Fiorillo C, Becatti M. , et al. Fibrin resistance to lysis in patients with pulmonary hypertension other than thromboembolic. Am J Respir Crit Care Med 2010; 181 (09) 992-996
    CrossrefPubMedGoogle Scholar
  • 14 Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327 (02) 76-81
    CrossrefPubMedGoogle Scholar
  • 15 Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997; 112 (03) 714-721
    CrossrefPubMedGoogle Scholar
  • 16 Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest 2006; 130 (02) 545-552
    CrossrefPubMedGoogle Scholar
  • 17 Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J 2006; 28 (05) 999-1004
    CrossrefPubMedGoogle Scholar
  • 18 Humbert M, Sitbon O, Chaouat A. , et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173 (09) 1023-1030
    CrossrefPubMedGoogle Scholar
  • 19 Robbins IM, Kawut SM, Yung D. , et al. A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 27 (03) 578-584
    CrossrefPubMedGoogle Scholar
  • 20 Aytekin M, Aulak KS, Haserodt S. , et al. Abnormal platelet aggregation in idiopathic pulmonary arterial hypertension: role of nitric oxide. Am J Physiol Lung Cell Mol Physiol 2012; 302 (06) L512-L520
    CrossrefPubMedGoogle Scholar
  • 21 Kawut SM, Bagiella E, Lederer DJ. , et al; ASA-STAT Study Group. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation 2011; 123 (25) 2985-2993
    CrossrefPubMedGoogle Scholar
  • 22 Humbert M. The burden of pulmonary hypertension. Eur Respir J 2007; 30 (01) 1-2
    CrossrefPubMedGoogle Scholar
  • 23 Rich S, Dantzker DR, Ayres SM. , et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107 (02) 216-223
    CrossrefPubMedGoogle Scholar
  • 24 Humbert M, Sitbon O, Yaïci A. , et al; French Pulmonary Arterial Hypertension Network. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36 (03) 549-555
    CrossrefPubMedGoogle Scholar
  • 25 Benza RL, Miller DP, Gomberg-Maitland M. , et al. Predicting survival in pulmonary arterial hypertension: Insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation 2010; 122 (02) 164-172
    CrossrefPubMedGoogle Scholar
  • 26 Hoeper MM, Huscher D, Ghofrani HA. , et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 2013; 168 (02) 871-880
    CrossrefPubMedGoogle Scholar
  • 27 Mercurio V, Peloquin G, Bourji KI. , et al. Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact. Pulm Circ 2018; 8 (02) 2045894018769874
    CrossrefPubMedGoogle Scholar
  • 28 Bertoletti L, Delavenne X, Montani D. Antithrombotics in pulmonary hypertension: more work needed before we turn to newer agents!. Eur Respir J 2013; 41 (04) 775-777
    CrossrefPubMedGoogle Scholar
  • 29 Bertoletti L, Mismetti P, Decousus H. Letter by Bertoletti et al regarding article, “Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)”. Circulation 2014; 130 (12) e108
    PubMedGoogle Scholar
  • 30 Gabriel L, Delavenne X, Bedouch P. , et al. Risk of direct oral anticoagulant bioaccumulation in patients with pulmonary hypertension. Respiration 2016; 91 (04) 307-315
    CrossrefPubMedGoogle Scholar
  • 31 Roldan T, Rios JJ, Villamañan E, Waxman AB. Complications associated with the use of oral anticoagulation in patients with pulmonary arterial hypertension from two referral centers. Pulm Circ 2017; 7 (03) 692-701
    CrossrefPubMedGoogle Scholar
  • 32 Jensen AS, Idorn L, Thomsen C. , et al. Prevalence of cerebral and pulmonary thrombosis in patients with cyanotic congenital heart disease. Heart 2015; 101 (19) 1540-1546
    CrossrefPubMedGoogle Scholar
  • 33 Giannakoulas G, Boutsikou M. The Gordian knot of thromboembolism in congenital heart disease. Heart 2015; 101 (19) 1523-1524
    CrossrefPubMedGoogle Scholar
  • 34 Pepke-Zaba J, Ghofrani H-A, Hoeper MM. Medical management of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2017; 26 (143) 160107
    CrossrefPubMedGoogle Scholar
  • 35 Konstantinides SV, Meyer G, Becattini C. , et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
    CrossrefPubMedGoogle Scholar
  • 36 Sanchez O, Benhamou Y, Bertoletti L. , et al. Recommendations of good practice for the management of thromboembolic venous disease in adults. Short version [in French]. Rev Mal Respir 2019; 36 (02) 249-283
    CrossrefPubMedGoogle Scholar
  • 37 Grünig E, Benjamin N, Krüger U. , et al. General measures and supportive therapy for pulmonary arterial hypertension: updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol 2018; 272S: 30-36
    CrossrefPubMedGoogle Scholar
  • 38 Ngian GS, Stevens W, Prior D. , et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 2012; 14 (05) R213
    CrossrefPubMedGoogle Scholar
  • 39 Olsson KM, Delcroix M, Ghofrani HA. , et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014; 129 (01) 57-65
    CrossrefPubMedGoogle Scholar
  • 40 Preston IR, Roberts KE, Miller DP. , et al. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation 2015; 132 (25) 2403-2411
    CrossrefPubMedGoogle Scholar
  • 41 Khan MS, Usman MS, Siddiqi TJ. , et al. Is anticoagulation beneficial in pulmonary arterial hypertension?. Circ Cardiovasc Qual Outcomes 2018; 11 (09) e004757
    PubMedGoogle Scholar
  • 42 Calderone A, Stevens W, Prior D. , et al. Multicentrerandomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. BMJ Open 2016; 6 (12) e011028
    CrossrefPubMedGoogle Scholar
  • 43 Jose A, Eckman MH, Elwing JM. Anticoagulation in pulmonary arterial hypertension: a decision analysis. Pulm Circ 2019; 9 (04) 2045894019895451
    CrossrefPubMedGoogle Scholar
  • 44 Żyłkowska J, Kurzyna M, Pietura R. , et al. Recurrent hemoptysis: an emerging life-threatening complication in idiopathic pulmonary arterial hypertension. Chest 2011; 139 (03) 690-693
    CrossrefPubMedGoogle Scholar
  • 45 Henkens IR, Hazenoot T, Boonstra A, Huisman MV, Vonk-Noordegraaf A. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension. Eur Respir J 2013; 41 (04) 872-878
    CrossrefPubMedGoogle Scholar
  • 46 Jujo-Sanada T, Tanabe N, Sakao S. , et al. The anticoagulant effects of warfarin and the bleeding risk associated with its use in patients with chronic thromboembolic pulmonary hypertension at a specialist center in Japan: a retrospective cohort study. Pulm Circ 2017; 7 (03) 684-691
    CrossrefPubMedGoogle Scholar
  • 47 Schulman S, Kearon C. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J ThrombHaemost 2005; 3 (04) 692-694
    CrossrefPubMedGoogle Scholar
  • 48 Ogawa A, Matsubara H, Fujio H. , et al. Risk of alveolar hemorrhage in patients with primary pulmonary hypertension--anticoagulation and epoprostenol therapy. Circ J 2005; 69 (02) 216-220
    CrossrefPubMedGoogle Scholar
  • 49 Nieto JA, Camara T, Gonzalez-Higueras E. , et al; RIETE Investigators. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. ThrombHaemost 2008; 100 (05) 789-796
    PubMedGoogle Scholar
  • 50 Clinicaltrials.gov. Bleeding frequency under anticoagulant treatment in pulmonary hypertension (HEMA-HTP), (NCT02800941), Available at: https://clinicaltrials.gov/ct2/show/NCT02800941?term=anticoagulant&cond=Pulmonary+Arterial+Hypertension&draw=2&rank=1 . Published 2016. Accessed May 25, 2020
    PubMed
  • 51 Mai V, Bertoletti L, Cucherat M. , et al. Extended anticoagulation for the secondary prevention of venous thromboembolic events: an updated network meta-analysis. PLoS One 2019; 14 (04) e0214134
    CrossrefPubMedGoogle Scholar
  • 52 Mai V, Guay CA, Perreault L. , et al. Extended anticoagulation for VTE: a systematic review and meta-analysis. Chest 2019; 155 (06) 1199-1216
    CrossrefPubMedGoogle Scholar
  • 53 López-López JA, Sterne JAC, Thom HHZ. , et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 2017; 359: j5058
    CrossrefPubMedGoogle Scholar
  • 54 Eikelboom JW, Connolly SJ, Brueckmann M. , et al; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369 (13) 1206-1214
    CrossrefPubMedGoogle Scholar
  • 55 Pengo V, Denas G, Zoppellaro G. , et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132 (13) 1365-1371
    PubMedGoogle Scholar
  • 56 Spangler ML, Saxena S. Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli. Clin Ther 2010; 32 (01) 53-56
    CrossrefPubMedGoogle Scholar
  • 57 Treiber A, Schneiter R, Häusler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug MetabDispos 2007; 35 (08) 1400-1407
    PubMedGoogle Scholar
  • 58 Walker G, Mandagere A, Dufton C, Venitz J. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers. Br J Clin Pharmacol 2009; 67 (05) 527-534
    CrossrefPubMedGoogle Scholar
  • 59 Roldan T, Villamañán E, Rios JJ, Waxman AB. Assessment of the quality of anticoagulation management in patients with pulmonary arterial hypertension. Thromb Res 2017; 160 (October): 83-90
    CrossrefPubMedGoogle Scholar
  • 60 Delbeck M, Nickel KF, Perzborn E. , et al. A role for coagulation factor Xa in experimental pulmonary arterial hypertension. Cardiovasc Res 2011; 92 (01) 159-168
    CrossrefPubMedGoogle Scholar
  • 61 Olsson KM, Wiedenroth CB, Kamp J-C. , et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. Eur Respir J 2017; 49 (06) 1602409
    CrossrefPubMedGoogle Scholar
  • 62 Bunclark K, Newnham M, Chiu YD. , et al. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. J ThrombHaemost 2020; 18 (01) 114-122
    CrossrefPubMedGoogle Scholar
  • 63 Bertoletti L, Jaïs X, Bezzeghoud S, Delavenne X. Direct oral anticoagulants: Still too early for prime time after pulmonary endarteriectomy?. J ThrombHaemost 2020; 18 (03) 758-759
    CrossrefPubMedGoogle Scholar
  • 64 Margelidon-Cozzolino V, Hodin S, Jacqueroux E, Delézay O, Bertoletti L, Delavenne X. In vitro assessment of pharmacokinetic drug-drug interactions of direct oral anticoagulants: type 5-phosphodiesterase inhibitors are inhibitors of rivaroxaban and apixaban efflux by P-glycoprotein. J Pharmacol Exp Ther 2018; 365 (03) 519-525
    CrossrefPubMedGoogle Scholar
  • 65 Jacqueroux E, Mercier C, Margelidon-Cozzolino V, Hodin S, Bertoletti L, Delavenne X. In vitro assessment of P-gp and BCRP transporters-mediated drug-drug interactions of riociguat with direct oral anticoagulants. Fundam Clin Pharmacol 2020; 34 (01) 109-119
    CrossrefPubMedGoogle Scholar
  • 66 Margelidon-Cozzolino V, Delavenne X, Catella-Chatron J. , et al. Indications and potential pitfalls of anticoagulants in pulmonary hypertension: would DOACs become a better option than VKAs?. Blood Rev 2019; 37: 100579
    CrossrefPubMedGoogle Scholar
  • 67 Cannon JE, Su L, Kiely DG. , et al. Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy: results from the United Kingdom national cohort. Circulation 2016; 133 (18) 1761-1771
    CrossrefPubMedGoogle Scholar
  • 68 Bunclark K, Ansaripour A, Sheares K, Toshner M. Response to letter to the editor: direct oral anticoagulants in thrombotic antiphospholipid syndrome associated with chronic thromboembolic pulmonary hypertension. J ThrombHaemost 2020; 18 (03) 756-757
    CrossrefPubMedGoogle Scholar
  • 69 Jiang X, Du Y, Cheng CY. , et al. Antiphospholipid syndrome in chronic thromboembolic pulmonary hypertension: a well-defined subgroup of patients. ThrombHaemost 2019; 119 (09) 1403-1408
    PubMedGoogle Scholar
  • 70 Porres-Aguilar M, Kahn SR, Hirsch AM. Direct oral anticoagulants in thrombotic antiphospholipid syndrome associated with chronic thromboembolic pulmonary hypertension. J ThrombHaemost 2020; 18 (03) 755-756
    CrossrefPubMedGoogle Scholar